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Predictive Factors for Ureteral Double-J-Stent-Related
Symptoms: A Prospective, Multivariate Analysis
Chen-Hsun Ho,1,3 Huai-Ching Tai,1 Hong-Chiang Chang,1 Fu-Chang Hu,2 Shyh-Chyan Chen,1
Yuan-Ju Lee,1 Jun Chen,1 Kuo-How Huang1*
Background/Purpose: Whether the length of stent affects stent-related symptoms after urological proce-
dures remains controversial. We aimed to evaluate the predictive factors for stent-related urinary tract
symptoms after uncomplicated ureteroscopic lithotripsy (URSL).
Methods: We prospectively recruited a total of 59 patients who underwent URSL and 6-Fr double-J
ureteral stent placement. The demographic and perioperative data and stent characteristics, including the
length (22, 24 or 26 cm), position of proximal end (upper calyx or pelvis), position of distal end (crossing
midline or not), and configurations of both ends (complete or incomplete curl) were recorded. All pa-
tients completed a self-administered questionnaire to evaluate the stent-related urinary symptoms, blad-
der pain, flank pain and hematuria 1 week after the procedure. All variables were analyzed by a proportional
odds logistic regression model.
Results: Twenty-two male (37.3%) and 37 (62.7%) female patients were enrolled in this study. Their
mean age was 53.7 ± 12.9 years. The mean body height was 161.9 ± 7.9 cm (range, 145.9–178 cm). In multi-
variate analysis, the 26-cm stent was independently associated with the severity of frequency, urgency, and
nocturia symptoms. Crossing the midline of the distal end was significantly associated with urge incon-
tinence. The 24-cm and 26-cm stents were both very strongly associated with the severity of hematuria.
Crossing the midline of the distal end was significantly associated with bladder pain.
Conclusion: The length of stent and crossing the midline of the distal end were significantly associated
with stent-related symptoms after URSL. Selection of the proper length of double-J stent is the most 
important factor in minimizing stent-related symptoms.
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Endourological procedures are commonly per-
formed worldwide. The double-J ureteral stent is
widely used to relieve or prevent ureteral obstruc-
tion after these procedures. Although insertion of
a ureteral stent maintains ureteral patency and
ensures drainage, some patients encounter some
discomfort such as irritative bladder symptoms,
hematuria, bladder pain, and flank pain; all of
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which have a negative impact on the quality 
of life.1–3 The most common complaints after
ureteroscopic stone lithotripsy (URSL) are associ-
ated with stents left in place postoperatively. The
exact pathophysiology of stent-related symptoms
remains unknown. Bladder symptoms are thought
to be a result of mucosal irritation of the nerve
located in the submucosa in the bladder trigone.
Flank pain is thought to be due to reflux of urine
from the bladder to the kidney, especially during
micturition. The relationship between stent char-
acteristics such as diameter, length, material, soft-
ness, position, and curl completeness and the
stent-related symptoms have been investigated by
several researchers.4–13 However, the exact factors
that affect the stent-related symptoms remain un-
clear. In the present study, we prospectively col-
lected 59 patients who underwent uncomplicated
URSL with the placement of a double-J stent. We
evaluated the urinary symptoms by a specific ques-
tionnaire and clarified the predictive factors for
stent-related symptoms by multivariate analysis.
Patients and Methods
After obtaining informed consent, we prospec-
tively evaluated 59 eligible patients with ureteral
stones diagnosed by intravenous urography who
underwent URSL in a single institute from August
2007 to April 2008. All patients were anesthetized
intravenously with propofol. The stones were
disintegrated by a semirigid 6.5-Fr ureteroscope
(Richard Wolf USA, Vernon Hills, IL, USA) with a
holmium–YAG laser. One of three lengths of 6-Fr
double-J ureteral stent was inserted at the end of
the operation (22 cm, 24 cm or 26 cm). All of the
stents were made of polyurethane (Cook Ireland
Ltd., Limerick, Ireland). The double-J stent was
inserted retrogradely via a guidewire under direct
ureteroscopic vision at the end of the procedure.
We chose the stent length randomly. The in-
dwelled Foley catheter was removed and the pa-
tient was discharged on the next day after URSL.
All procedures were completed without compli-
cations (no ureteral injury or intraoperative stone
migration to the kidneys). After the operation,
cephalexin (500 mg, 4 times daily) and acetamin-
ophen (500 mg, 4 times daily) were prescribed for
4 days. The exclusion criteria included: (1) con-
comitant renal stones or residual stones on the
postoperative plain film (KUB) and renal ultra-
sonography; (2) pre-procedural urological diseases
that caused lower urinary tract symptoms or
bladder pain, including prostate disease (benign
prostate hypertrophy, chronic prostatitis, and
prostate cancer), overactive bladder, interstitial
cystitis, painful bladder syndrome, urinary incon-
tinence, and urinary tract infection; (3) long-term
medications with α-blockers, anticholinergics or
analgesics; and (4) the presence of procedure-
associated complications such as fragment migra-
tion to the kidneys, ureteral injury, urinary tract
infection, or stent malposition.
One week after URSL, a plain (KUB) film and
renal ultrasonography images were obtained at
the clinic for all the patients to confirm the stent
position and the presence of residual stones. All
films were reviewed by a single urologist. In addi-
tion to the length of stent, four characteristics on
the image were recorded: (1) the position of the
proximal curl (in the upper pole or the renal
pelvis); (2) the position of the distal curl (crossing
the midline or not); (3) the completeness of the
proximal curl; and (4) the completeness of the dis-
tal curl. At the same time, all patients were asked
to complete the self-administered questionnaire in
outpatient clinics to assess their symptoms in the
period of stenting. The investigated symptoms in-
cluded frequency, urgency, nocturia, urge inconti-
nence, hematuria, flank pain, and bladder pain
(see Appendix). To assess the severity of each symp-
tom, the questions were adapted from the ques-
tionnaire of the International Prostate Symptoms
Score (IPSS). The severity of flank and bladder pain
was evaluated with a pain score, of 0–5, with
0 = pain, and 5 = the worst pain ever experienced.
Statistical analysis was performed with SAS
version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Two-tailed p ≤ 0.05 was considered statistically
significant. Continuous data were expressed as
mean ± standard deviation unless otherwise
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specified. Percentages were calculated for cate-
gorical variables. Descriptive analysis of all avail-
able variables was performed. In multivariate
analysis, the commonly used proportional odds
logistic regression model was fitted to the observed
polychotomous categorical response with ordered
categories. Each symptom question was originally
scored as 0 for “no symptom” and 1–5 to indicate
the chance of having the symptom, or its severity
from low to high (Appendix). We re-classified the
0–5 symptom scores into three ordered grading
categories as the polychotomous response variable:
1 = no symptom (for symptom score = 0); 2 = mild
symptom (for symptom scores = 1 or 2); and
3 = severe symptom (for symptom scores = 3–5).
Basic model-fitting techniques for (1) variable
selection, (2) goodness-of-fit (GOF) assessment,
and (3) regression diagnostics (e.g. test of the
proportional odds assumption, residual analysis,
detection of influential cases, and check for
multicollinearity) were used in our regression
analyses to ensure the quality of the results. In the
stepwise variable selection, both the significant
level for entry (SLE) and stay (SLS) were set to
≥ 0.15, and the covariates including age, sex, body
weight, body height, stone size, stone position,
operation time, stent length (22 cm, 24 cm or
26 cm), crossing midline of distal end (yes vs. no),
position of proximal end (upper calyx vs. pelvis),
curl of distal end (complete vs. incomplete), curl
of proximal end (complete vs. incomplete) were
considered. GOF measures, such as the percent-
age of concordant pairs, estimated area under the
receiver operating characteristic curve, and the
adjusted generalized R2, and the GOF tests, in-
cluding the deviance GOF test and Pearson χ2
GOF test, were examined to assess the GOF of
each fitted logistic regression model.
Results
The demographic and stent-related characteris-
tics of the 59 patients are listed in Table 1. There
were 22 male (37.3%) and 37 (62.7%) female
subjects. The mean age was 53.7 ± 12.9 years. The
mean body height and weight were 161.9 ±
7.9 cm (range, 145.9–178 cm) and 66.1 ± 13.3 kg
(range, 54–95 kg), respectively. The stone was lo-
cated in the right ureter in 35 (59.3%) patients
and in the left ureter in 24 (40.7%). The mean
stone size was 93.1 ± 39.5 mm2, and mean oper-
ation time was 40.6 minutes.
The frequency distribution of double-J-related
symptoms is shown in Table 2. The incidence of
Table 1. Patient demographic and stent-related
characteristics (n = 59)*
Variables Value
Age (yr) 53.7 ± 12.9
Sex
Male 22 (37.3)
Female 37 (62.7)
Body height (cm) 161.9 ± 7.9
Body weight (kg) 66.1 ± 13.3
Laterality
Right side 35 (59.3)
Left side 24 (40.7)
Stone size (mm2) 93.1 ± 39.5
Stone position
Upper 1/3 26 (44.1)
Middle 1/3 9 (15.3)
Lower 1/3 24 (40.7)
Operation time (min) 40.6 ± 23.2
Double-J length 
22 cm 16 (27.1)
24 cm 17 (28.8)
26 cm 26 (44.1)
Distal end across midline
Yes 34 (57.6)
No 25 (42.4)
Proximal end position
Upper calyx 38 (64.4)
Renal pelvis 21 (35.6)
Proximal end curl
Complete curl 51 (86.4)
Incomplete curl 8 (13.6)
Distal end curl
Complete curl 50 (84.8)
Incomplete curl 9 (15.3)
*Data presented as n (%) or mean ± standard deviation.
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the irritative symptoms was 91.5% for nocturia,
86.4% for frequency, 76.3% for urgency, and
40.7% for urge incontinence. The mean scores for
individual symptoms were: 1.69 ± 1.61 (range,
0–5) for frequency; 1.46 ± 1.64 (range, 0–5) for
urgency; 1.44 ± 1.34 (range, 0–5) for nocturia;
and 0.86 ± 1.37 (range, 0–5) for urge inconti-
nence. Bladder pain was presented in 41 of 59
(69.5%) patients with the same incidence of flank
pain. Gross hematuria was noted in 47 (79.7%)
patients. No patients needed to visit the emer-
gency room due to severe stent-related symptoms
or procedure-associated complications.
Multivariate analysis of the risk factors associ-
ated with each of the five lower urinary tract
symptoms (frequency, urgency, urge incontinence,
nocturia, and hematuria) in 59 patients is shown
in Table 3. The 26-cm stent was independently
associated with the severity of frequency, urgency
and nocturia symptoms. The corresponding esti-
mated odds ratios (ORs) were 4.638 [95% con-
fidence interval (CI) = 1.59–13.53; p = 0.0050)],
4.126 (95% CI = 1.482–11.484; p = 0.0067), and
3.618 (95% CI = 0.996–13.15; p= 0.0508), respec-
tively. Crossing the midline of the distal end was
significantly associated with urge incontinence
(OR = 4.767; 95% CI = 1.604–14.16; p = 0.0049).
Finally, the 24-cm and 26-cm stents were both
very strongly associated with severity of hema-
turia (OR = 18.081; 95% CI = 3.054–107.042; p =
0.0014 and OR = 12.683; 95% CI = 3.002–53.593;
p = 0.0006, respectively). Crossing the midline of
the distal end was significantly associated with
bladder pain (OR=8.475; 95% CI=1.749–41.066;
p = 0.0079). The variables of right side and body
weight were not significantly related to flank
pain (p > 0.05).
Discussion
Placement of a double-J ureteral stent has been
widely used in urological surgery since it was first
described by Zimskind in 1967.14 Although it
ensures urinary drainage, significant morbidity 
is associated with the placement of a ureteral
stent. Joshi et al reported on the adverse effects of
double-J stents, and have suggested that 80% of
patients experience bothersome urinary symp-
toms and pain related to the stent.1,2 Our results
showed a similar prevalence. Stent-related uri-
nary symptoms were thought to have been due
to bladder irritation by the stent. Several studies
have investigated associated factors that might
cause urinary symptoms, but the results remain
controversial.4,5,7–13,15,16
El-Nahas et al an analysis of factors responsi-
ble for ureteral-stent-associated discomfort. They
enrolled patients with various diagnoses and
treatment procedures. In addition, they coded
symptoms by recording whether symptoms were
present or not, which did not represent the exact
Table 2. Frequency distribution of double-J-related symptoms (n = 59)*
Grading
Symptom No symptom Mild symptom Severe symptom
0* 1 2 3 4 5
Frequency 8 (13.6) 5 (8.47) 18 (30.5) 6 (10.2) 13 (22.0) 9 (15.3)
Urgency 14 (23.7) 6 (10.2) 16 (27.1) 4 (6.8) 13 (22.0) 6 (10.2)
Urge incontinence 35 (59.3) 14 (23.7) 3 (5.1) 4 (6.8) 3 (5.1) 0 (0)
Nocturia 5 (8.5) 17 (28.8) 27 (45.8) 5 (8.5) 2 (3.4) 3 (5.1)
Flank pain 18 (30.5) 3 (5.1) 9 (15.3) 9 (15.3) 14 (23.7) 6 (10.2)
Urethral pain 18 (30.5) 2 (3.4) 8 (13.6) 11 (18.6) 14 (23.7) 6 (10.2)
Hematuria 12 (20.3) 5 (8.5) 1 (1.7) 25 (42.4) 16 (27.1) 0 (0)
*Data presented as n (%). These symptom scores from 0 to 5 were reclassified into three categories as indicated in the table subheadings.
In polychotomous logistic regression analysis, “No symptom” was re-coded as 0, “Mild symptom” as 1, and “Severe symptom” as 2.
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severity of stent-related symptoms. They used a
logistic regression model for multivariate analy-
sis and have concluded that the proper position
of the stent coils and shorter stenting duration
decrease patient discomfort.16 We have demon-
strated previously that stent length is associated
with the position of the distal loop and the related
urinary symptoms in a retrospective research,
without analyzing perioperative factors.13 In the
present study, we prospectively recruited patients
who underwent URSL, and analyzed all possible
variables by the proportional odds logistic regres-
sion model to determine the factors that were sig-
nificantly associated with stent-related symptoms.
Basic model-fitting techniques for (1) variable
selection, (2) GOF assessment, and (3) regression
diagnostics were used in our regression analysis
to ensure the quality of the results.
It is reasonable to postulate that an overlong
stent with a longer intravesical segment might
cause more irritation of the bladder, and conse-
quently increase the severity of discomfort. A few
previous studies have demonstrated results that
are consistent with ours. Rane et al reported that
stents crossing the midline of the bladder or
those with incomplete loops at the lower end
significantly increase morbidity. They have con-
cluded that proper stent length and placement
appropriate to each patient’s ureteral length are
necessary to improve comfort.9 Liatsikos et al also
compared the symptoms associated with place-
ment of the proximal curl in the upper pole and
renal pelvis. They have proposed that position-
ing of the proximal end of the double-J stent in
the upper pole of the kidney appears to be better
tolerated by patients than is standard insertion in
the renal pelvis, in terms of urgency, dysuria and
quality of life.8 Al-Kandari et al also demonstrated
that flank pain, urgency, dysuria and worsened
quality of life are significantly more common
among patients who have longer stents.15 Some
studies have revealed different results. Irani et al
evaluated the urinary symptoms of 39 patients after
inserting a 28-cm ureteral stent. Most of the pa-
tients could tolerate the stent-related discomfort.11
The exact correlation between stent length and
stent-related symptoms remains inconclusive.
Our results demonstrated that a 26-cm stent was
significantly associated with the severity of noc-
turia, frequency and urgency. Crossing the mid-
line of the distal end had a significant impact on
urge incontinence. Bladder pain could be inde-
pendently predicted by crossing the midline of
the distal end. Hematuria was significantly asso-
ciated with 24-cm and 26-cm stents compared
with 22-cm stents. These results yield useful 
information that help to clarify the issue.
Several studies have suggested methods to de-
termine the correct stent length, including direct
measurement of the ureter itself using a guidewire,
an endocatheter ruler, formulas based on preoper-
ative intravenous urography, and formulas based
on patient height.6,17–20 None of the methods have
been proven accurate or applicable to clinical
practice. Shah et al measured ureteral length using
a ureteral catheter and have compared the mea-
sured length with the height of 25 patients.19 The
mean patient height was 164.8 cm (range, 156–
180 cm) and ureteral length was 23.46 cm (range,
16–29 cm). Patient height did not correlate with
ureteral length. Conversely, Pilcher et al found
that patient height was correlated with ureteral
length more accurately than direct endoluminal
measurement in 35 patients. They have proposed
the use of 22-cm stents for patients shorter than
178 cm, 24-cm stents for patients between 178
and193 cm, and 26-cm stents for patients taller
than 193 cm. The main criticism of their study is
that subjective symptom scores were not deter-
mined. Our results also indicated that the 22-cm
stent was appropriate for the study objects whose
mean body height was 161.9 cm (range, 145.9–
178.0 cm). In addition, subjects treated with 
22-cm stent experienced less stent-related symp-
toms compared with those treated with 24- and
26-cm stent.
The present study prospectively analyzed all
clinically available parameters by multivariate
analysis to establish the predictive factors for stent-
related symptoms after uncomplicated URSL. A
small number of patients and the non-randomized
design were the major limitations of the study.
Prediction of ureteral stent-related symptoms
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However, our results provide useful information
for endourologists who are choosing an appro-
priate double-J stent after uncomplicated URSL.
In conclusion, the length of stent and midline
crossing had a significant effect on stent-related
urinary symptoms during stenting after uncom-
plicated URSL. The choice of an appropriate length
of stent might be the most important issue that
we should consider to reduce the severity of stent-
related symptoms.
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Appendix. The questionnaire was used to assess the symptoms following stent insertion:
Q1. Over the past week, how often have you had to urinate again less than 2 hours after you finished urinating?
(0) Not at all, (1) Less than one in five times, (2) Less than half the time, (3) About half the time, 
(4) More than half the time, (5) Almost always
Q2. Over the past week, how often have you found it difficult to postpone urination?
(0) Not at all, (1) Less than one in five times, (2) Less than half the time, (3) About half the time, 
(4) More than half the time, (5) Almost always
Q3. Over the past week, how many times did you most typically get up to urinate from the time you went to
bed until the time you got up in the morning?
(0) Never, (1) Once, (2) Twice, (3) Three times, (4) Four times, (5) Five times or more
Q4. Over the past week, how often have you had urine leakage before you can reach the toilet?
(0) Not at all, (1) Less than one in five times, (2) Less than half the time, (3) About half the time, 
(4) More than half the time, (5) Almost always
Q5. Over the past week, have you had any bladder pain? Please try to grade the severity on a scale of 0 to 5
(with 0 = no pain and 5 = the worst pain ever experienced).
(0) (1) (2) (3) (4) (5)
Q6. Over the past week, have you ever had any flank pain? Please try to grade the severity on a scale of 0 to 5
(with 0 = no pain and 5 = the worst pain ever experienced).
(0) (1) (2) (3) (4) (5)
Q7. Over the past week, how often have you ever had hematuria?
(0) Not at all, (1) Less than one in five times, (2) Less than half the time, (3) About half the time, 
(4) More than half the time, (5) Almost always
